Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective blinded, randomized controlled study. The study will include three study arms:
Patients undergoing laparoscopic hysterectomies will be randomized to one of either "Ultravision" (study arm 1) or "no Ultravision" (study arm 2, i.e. the current standard of care) groups. The study will be conducted blinded to the investigator during the procedure through patient discharge. The Ultravision system will be present in both, with the generator covered (not seen by user) and either on or off depending on the randomization. 30 patients will be enrolled, 15 per group. Five patients undergoing myomectomy will have their procedures conducted using the Ultravision (study Arm 3).
Ultravision is cleared for use in all laparoscopic surgery i.e. including laparoscopic hysterectomy and myomectomy, in the United States. However, the clinical benefits arising from its use in gynecology have not yet been quantitatively assessed and published in an independent medical journal.
Study Purpose:
There are three main study objectives
Background: The smoke generated by electrosurgical devices in the process of dissection of tissues during laparoscopy can obscure the surgical visual field. Laparoscopic hysterectomy and laparoscopic myomectomy are procedures that produce a considerable amount of smoke, which impedes the operating surgeon. It is often necessary to suspend the surgery to allow the smoke to dissipate, or more commonly open a laparoscopic port to vent the smoke into the room, adding to the operating time. It is also common to remove the laparoscope to clean the lens because it can be soiled by the smoke as well. In order to enhance the dissipation of smoke and maintain an adequate pneumoperitoneum it is often necessary to increase the flow of carbon dioxide (CO2) from the insufflator. Surgical smoke handling during laparoscopic surgery results in an increase of the known risks to the patient of using excessive CO2; as well exposing the operating room staff to the smoke which may create a potential health concern. The electrostatic-precipitation of laparoscopic smoke is a new technique, marketed under the name Ultravision©, making it possible to precipitate the smoke as it is created, thereby actively eliminating it from the field of view. Safety and feasibility studies have been carried out allowing it to be placed on the market in Europe, Japan and the United States. A randomized study of its clinical effectiveness (ref: Ansell J. Surg, Endosc. (2014) 28: 2057-2065) showed that electrostatic-precipitation significantly improved visibility (reduction of visual impairment) and reduced surgery time in laparoscopic cholecystectomy. Ultravision is cleared for use in all laparoscopic surgery i.e. including laparoscopic hysterectomy and myomectomy, in the United States. However, the clinical benefits arising from its use in gynecology have not yet been quantitatively assessed and published in an independent medical journal.
Study Purpose: here are three main study objectives;
Primary Hypothesis: The primary hypothesis being tested in this study is that using Ultravision during laparoscopic hysterectomy and myomectomy improves visualization similar to that reported when used in laparoscopic cholecystectomy without the need for CO2 exchange and that, by doing so, the amount of CO2 that the patient is exposed to is reduced compared to the current standard of care.
Secondary hypothesis: There are two aspects to CO2 exposure during laparoscopic surgery: the amount of gas used and the intra-abdominal pressure of the pneumoperitoneum. Ultravision has already been shown in laparoscopic cholecystectomy to minimize the amount of CO2 that a patient is exposed to during laparoscopic surgery because it does not rely on the process of dilution using ongoing CO2 supply from the insufflator. Decreasing the intra-abdominal pressure below the conventional 12-15 mmHg during laparoscopic surgery has been shown by others to lead to improved clinical outcomes in other laparoscopic procedures.
In this study the target abdominal pressure for all procedures conducted will be 10mmHg. The ability to maintain that pressure during the procedure in the different study arms will be reported and compared. In addition to this secondary endpoint other procedure data will be collected to assess the potential impact of the Ultravision technology on procedure characteristics such as adverse events, procedure time, patient temperature, patient end tidal CO2 level, post-op medications for pain etc.
INTENDED USE: The Ultravision™ System is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery.
DEVICE DESCRIPTION: The Ultravision™ System is an accessory to electrosurgical instruments that is used to clear the surgical smoke generated during their use and as such will only be used when such devices are in use. An example of the effect of the Ultravision™ System during use to improve the visualization of the field of view.
The system includes the following elements: Standalone battery-operated generator unit Ionwand™, which is introduced into the abdomen of the patient through either the Ultravision™ 5mm Trocar or a 2.5mm percutaneous catheter and provides the source of the electrons that create the negative ions that transiently charge the surgical smoke particles. Other accessories include a patient return adaptor and battery recharging station.
US REGULATORY STATUS: The Ultravision™ System obtained regulatory clearance through US FDA's De Novo Classification Process (DEN 150022). The system has been in distribution in Europe since January 2014 and in the US since December of 2016, over 250 systems are currently in use. To date there have been no incident or medical device reports (patient injury reports) and there have been no product recalls.
SUBJECT IDENTIFICATION & SELECTION: Potential subjects will be identified from the clinical practice of the participating investigator or by their respective research staff. Each new subject presenting for evaluation or inclusion is to be assessed for adherence to the following inclusion/exclusion criteria. Patients are considered enrolled once it has been demonstrated that the inclusion/exclusion criteria have been met and the patient signs the informed consent.
SUBJECT INFORMED CONSENT: Referred patients presenting for diagnosis or treatment consistent with the inclusion criteria will undergo the informed consent process.
PREOPERATIVE PROTOCOL: Patients will be assessed preoperatively in accordance with the current standard of care. The Ultravision™ System will be set up in the OR for all cases. For randomized study arms 1 and 2, the system will be covered such that the electronic display is not visible to the investigator. The system will be turned off for all non-Ultravision procedures. For all procedures, the Ionwand will be inserted/introduced as described in the Instructions for Use.
SURGEON VISUALIZATION SURVEY: Immediately post procedure the investigator will be asked three questions:
POST PROCEDURE FOLLOW-UP PROTOCOL: Post procedure follow-up assessments include discharge and 2-week follow-up, which is the current standard of care.
ADVERSE EVENT CATEGORIES: For purposes of this protocol the adverse event definitions are derived from Good Clinical Practice (GCP) standards and FDA Guidance.
The signs, symptoms, and sequelae of an underlying adverse event (linked pathophysiologically to the AE) should not be reported as separate adverse events. All adverse events, of any type, are to be recorded on an "Adverse Event Form". Adverse events are to be characterized by their severity, relatedness the implant procedure, need for therapy, and resolution status.
Adverse events will initially be characterized as "serious" or "non-serious" by the study investigator.
ADVERSE EVENT ADJUDICATION: Events are to be initially judged by the investigator as to their relatedness to the study device, implant procedure, or "other etiology". The classifications will be "not related", "probably not related", "undetermined", "probably related", or "related".
REPORTING OF ADVERSE EVENTS AND UNANTICIPATED PROBLEMS Serious adverse events and Unanticipated Problems related to the research will be reported to the Mercy Institutional Review Board.
SUBSEQUENT SURGICAL INTERVENTIONS: Some complications may lead to a subsequent surgical intervention. The reason for each subsequent surgical intervention and the action taken is recorded on the case report form, along with the identification of the type subsequent surgical interventions according. The exact type of intervention must be specified.
PATIENT WITHDRAWAL: A patient may choose to withdraw from participation in the study at any time without penalty. If a patient chooses to withdraw they will still receive medical care consistent with the standard of care. The investigator may at their discretion withdraw a patient from participation. Examples include if the procedure necessitates conversion from laparoscopic to open technique, lack of adherence to visit schedule, adverse events, or safety concerns. For all withdrawals the date, point in the study, and reason for withdrawal will be recorded.
STUDY SUSPENSION/TERMINATION: If for any reason the principle investigator chooses to suspend or terminate the study, the IRB shall be informed of the decision and the basis of the decision.
PROVISION AND INVENTORY OF STUDY DEVICES: The device and required materials will be provided to the Investigator by Alesi Surgical Ltd.
DATA COLLECTION AND MANAGEMENT: The investigators are responsible for collecting the data from the study.
IMAGING DIAGNOSTICS: All imaging performed for patients is considered consistent with standard of care.
SAMPLE SIZE JUSTIFICATION: The sample size selected (15) per group is considered to be a number to allow for a meaningful comparison between the study arms conducted by a single investigator. As a post-market study intended to evaluate user satisfaction and relative impact the Ultravision™ System has on the procedure as opposed to demonstrating safety and efficacy, the sample size is considered to be sufficient for that purpose. This essential information is identified in the primary and secondary endpoints.
DATA ANALYSIS; Data collected will be summarized using descriptive statistics. For study success results must demonstrate a clinical benefit for the randomized Ultravision group compared to the no Ultravision group based upon the primary endpoint analysis. Additional exploratory analysis may be conducted during data analysis. Because the study is not statistically powered, analysis for primary and secondary endpoints will be conducted using comparative statistics with the caveat understood regarding the relatively small sample sizes for each group.
ADMINISTRATION: This study is being conducted as an "Investigator Sponsored" post-market study. The Investigator holds ultimate responsibility for the design, conduct, analysis, and reporting of the results from this study and is the primary contact for all matters related to this investigational plan. The Primary Investigator is also accountable for monitoring this investigation and performing those actions necessary to protect the scientific credibility of the way this study is conducted.
REGULATORY COMPLIANCE: The investigators and all research staff participating in this investigation are expected to adhere to this investigational plan, Good Clinical Practices, applicable privacy laws, the Declaration of Helsinki, and any approval requirements imposed by an Institutional Review Board. The study will be submitted for review and approval by the Mercy Institutional Review Board.
PRIVACY AND CONFIDENTIALITY: This study is to be performed in accordance with all applicable privacy laws. All data and information concerning subjects and their participation in this trial are considered confidential. Only authorized investigators and approved study personnel will have access to some portions of these confidential files. Institutional Review Boards and other regulatory authorities also have the right to inspect and copy records pertinent to this trial. All public reporting of the results of this study will eliminate identifiable references to the subjects.
RISK/BENEFIT ASSESSMENT: As a surgical accessory device, the Ultravision™ System does not administer any medical treatment. The risks associated with its use are consistent with other surgical accessories used in laparoscopic surgery. The device has been tested for sterility, biocompatibility, and electrical safety demonstrating that such risks have been mitigated to acceptable levels.The benefits that are being evaluated in this study are improved visualization, lower pressure of pneumoperitoneum, and CO2 consumption have the potential to favorably impact patient outcomes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ARM 1 | Active Comparator | Laparoscopic hysterectomy with use of the Ultravision System |
|
| ARM 2 | Placebo Comparator | Laparoscopic Hysterectomy per Standard of Care/no Ultravision System |
|
| ARM 3 | Active Comparator | Laparoscopic myomectomy with use of the Ultravision System. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ultravision System | Device | Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Surgical Field Visualization | Measure the quality of visualization in the laparoscopic field of view using a 5 point Visual Analog Scale. 0 is visible interference is imperceptible, 2-3 is perceptible to interfering, 4 is interfering, 5 is highly interfering) | End of procedure |
| Consumed CO2 | Amount of CO2 Consumed in liters from placement of all surgical ports to colpotomy (hysterectomy) or closure of last uterine defect (myomectomy) | End of procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Operative Procedure Disruption | Count of the number of times the operative procedure is interrupted or delayed due to clearing smoke | Intraoperative |
| Intra-abdominal Pressure | Maximum intra-abdominal pressure used measured in mmHg |
Not provided
Inclusion Criteria:
Subjects MUST meet all the following:
Exclusion Criteria:
Subjects MUST not have any of the following:
The study will enroll female patients who are indicated for laparoscopic hysterectomy or myomectomy.
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David J Levine, MD | Mercy Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mercy Hospital St. Louis | St Louis | Missouri | 63141 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | ARM 1 | Laparoscopic hysterectomy with use of the Ultravision System Ultravision System: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. |
| FG001 | ARM 2 | Laparoscopic Hysterectomy per Standard of Care/no Ultravision System Laparoscopic Hysterectomy: Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System |
| FG002 | ARM 3 | Laparoscopic myomectomy with use of the Ultravision System. Ultravision System: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ARM 1 | Laparoscopic hysterectomy with use of the Ultravision System Ultravision System: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Quality of Surgical Field Visualization | Measure the quality of visualization in the laparoscopic field of view using a 5 point Visual Analog Scale. 0 is visible interference is imperceptible, 2-3 is perceptible to interfering, 4 is interfering, 5 is highly interfering) | Posted | Number | participants | End of procedure |
|
Adverse event data was collected from screening/baseline through the 2-week follow up visit.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | ARM 1 | Laparoscopic hysterectomy with use of the Ultravision System Ultravision System: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Urinary retention | Renal and urinary disorders | Non-systematic Assessment | Inability to urinate |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| David Levine, MD | Mercy Hospital St. Louis | 314-251-7650 | David.Levine@Mercy.net |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 5, 2019 | Dec 17, 2019 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
STUDY DESIGN This is a prospective blinded, randomized controlled study. Arms 1 and 2: Patients enrolling in study arms 1 and 2 who are undergoing hysterectomy will be randomized to either the Ultravision™ System (Arm 1) or Standard of Care/no Ultravision (Arm 2) study arms.
Arm 3: Patients enrolling in study arm 3 who are undergoing a myomectomy will have their procedure conducted with the Ultravision™ System. The procedure is purported to generate the greatest smoke and therefore constitutes a worst-case challenge for the system.
All prescribed evaluations will be performed for all study arms.
STUDY SIZE Arms 1 and 2 (randomized) will enroll 15 patients each. Arm 3 will enroll an additional 5 patients.
DURATION The total duration of the study is expected to be approximately 6 months.
Not provided
Not provided
Patients will be randomized using a paper envelope system, just prior to surgery. Investigator will not be informed of the randomization assignment until after the patient is discharged (end of follow-up period). A simple envelope system is used. Pre-made study arm assignment envelopes will be created. Envelopes will be opened just prior to the procedure. For patients randomized & withdrawn prior to the procedure or converted to open procedure, replacement envelopes will be added to the envelope pool. To preserve blinding during the procedure, the Ultravision System consumable will be introduced into the patient, generator will appear operational during all procedures. The display will be covered during use so the investigator is not aware the system is on/off. If for any reason un blinding occurs, the reason will be recorded. Study assessments will be collected per protocol, but the data will not be pooled with blinded data for analysis.
|
| Laparoscopic Hysterectomy | Procedure | Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System |
|
| End of procedure |
| Number of Participants With Adjusted Intra-abdominal Pressure | The number of participants who had an adjustment in intra-abdominal pressure during the procedure | Intraoperative |
| Duration of Intra-abdominal Pressure Increase | Duration spent at first intra-abdominal pressure increase from the initial 10mmHg set point | Intraoperative |
| Temperature at Time 0 Min | Temperature in degrees Celsius at time 0 min during operative procedure | Intraoperative |
| Temperature at Time 15 Min | Temperature in degrees Celsius at 15 min during operative procedure | Intraoperative |
| Temperature at Time 30 Min | Temperature in degrees Celsius at 30 min during operative procedure | Intraoperative |
| Temperature at Time 45 Min | Temperature in degrees Celsius at 45 min during operative procedure | Intraoperative |
| Temperature at Time 60 Min | Temperature in degrees Celsius at 60 min during operative procedure | Intraoperative |
| End-Tidal CO2 Level at Time 0 | End-Tidal CO2 leve; recorded at 0 min during the operative procedure | Intraoperative |
| End-Tidal CO2 Level at Time 15 | End-Tidal CO2 level recorded at 15 min during the operative procedure | Intraoperative |
| End-Tidal CO2 Level at Time 30 | End-Tidal CO2 level recorded at 30 min during the operative procedure | Intraoperative |
| End-Tidal CO2 Level at Time 45 | End-Tidal CO2 level recorded at 45 min during the operative procedure | Intraoperative |
| End-Tidal CO2 Level at Time 60 | End-Tidal CO2 level recorded at 60 min during the operative procedure | Intraoperative |
| Duration of Procedure | Time from placement of last surgical port to colpotomy (hysterectomy) or closure of last uterine defect (myomectomy) | Intraoperative |
| Number of Participants With a Hospital Stay Less Than 24 Hours | The number of participants with a hospital duration of stay less than 24 hours recorded as "yes" or "no." Data represent the number of participants with a hospital stay less than 24 hours. | 2 weeks following procedure completion |
| Postoperative Pain Numerical Rating Scale | Post operative pain evaluated according to a numerical rating scale from 0 (no pain) to 10 (worst pain possible) | Before hospital discharge |
| Postoperative Pain Numerical Rating Scale | Post operative pain evaluated according to a numerical rating scale from 0 (no pain) to 10 (worst pain possible) | 2 weeks following procedure completion |
| Number of Participants That Received Post-operative Opioid Pain Medication | The number of participants that received post-operative opioid pain medication during hospital stay recorded as "yes" or "no." Data represent the number of participants that received post-operative opioid pain medication during hospital stay. | Post-operative hospitalization |
| Number of Participants That Received Post-operative Non-opioid Pain Medication | The number of participants that received post-operative non-opioid pain medication during hospital stay recorded as "yes" or "no." Data represent the number of participants that received post-operative non-opioid pain medication during hospital stay. | Post-operative hospitalization |
| Number of Participants Reporting Opioid Pain Medication Use at Follow up | The number of participants that reported opioid pain medication use at follow up visit recorded as "yes" or "no." Data represent the number of participants that reported opioid pain medication use at follow up. | 2 week follow up visit |
| Number of Participants Reporting Non-opioid Pain Medication Use at Follow up | The number of participants that reported non-opioid pain medication use at follow up visit recorded as "yes" or "no." Data represent the number of participants that reported non-opioid pain medication use at follow up. | 2 week follow up visit |
| Adverse Events Related to Procedure | Number of subjects with adverse events determined probably related or related to procedure | Intraoperative up to 2 weeks post procedure |
| Adverse Events Related to Smoke Clearing Device | Number of subjects with adverse events determined probably related or related to smoke clearing device | Intraoperative up to 2 week follow up visit |
| BG001 | ARM 2 | Laparoscopic Hysterectomy per Standard of Care/no Ultravision System Laparoscopic Hysterectomy: Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System |
| BG002 | ARM 3 | Laparoscopic myomectomy with use of the Ultravision System. Ultravision System: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| BMI | Body Mass Index | Mean | Standard Deviation | kg/m2 |
|
Laparoscopic Hysterectomy per Standard of Care/no Ultravision System Laparoscopic Hysterectomy: Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System |
| OG002 | ARM 3 | Laparoscopic myomectomy with use of the Ultravision System. Ultravision System: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. |
|
|
| Primary | Consumed CO2 | Amount of CO2 Consumed in liters from placement of all surgical ports to colpotomy (hysterectomy) or closure of last uterine defect (myomectomy) | Posted | Mean | Standard Deviation | Liters | End of procedure |
|
|
|
| Secondary | Operative Procedure Disruption | Count of the number of times the operative procedure is interrupted or delayed due to clearing smoke | Posted | Mean | Standard Deviation | Count of pauses for smoke clearing | Intraoperative |
|
|
|
| Secondary | Intra-abdominal Pressure | Maximum intra-abdominal pressure used measured in mmHg | Posted | Mean | Standard Deviation | mmHg | End of procedure |
|
|
|
| Secondary | Number of Participants With Adjusted Intra-abdominal Pressure | The number of participants who had an adjustment in intra-abdominal pressure during the procedure | Posted | Count of Participants | Participants | Intraoperative |
|
|
|
| Secondary | Duration of Intra-abdominal Pressure Increase | Duration spent at first intra-abdominal pressure increase from the initial 10mmHg set point | Posted | Mean | Standard Deviation | minutes | Intraoperative |
|
|
|
| Secondary | Temperature at Time 0 Min | Temperature in degrees Celsius at time 0 min during operative procedure | Posted | Mean | Standard Deviation | Degrees Celsius | Intraoperative |
|
|
|
| Secondary | Temperature at Time 15 Min | Temperature in degrees Celsius at 15 min during operative procedure | Posted | Mean | Standard Deviation | Degrees Celsius | Intraoperative |
|
|
|
| Secondary | Temperature at Time 30 Min | Temperature in degrees Celsius at 30 min during operative procedure | Posted | Mean | Standard Deviation | Degrees Celsius | Intraoperative |
|
|
|
| Secondary | Temperature at Time 45 Min | Temperature in degrees Celsius at 45 min during operative procedure | Posted | Mean | Standard Deviation | Degrees Celsius | Intraoperative |
|
|
|
| Secondary | Temperature at Time 60 Min | Temperature in degrees Celsius at 60 min during operative procedure | Posted | Mean | Standard Deviation | Degrees Celsius | Intraoperative |
|
|
|
| Secondary | End-Tidal CO2 Level at Time 0 | End-Tidal CO2 leve; recorded at 0 min during the operative procedure | Posted | Mean | Standard Deviation | Percent CO2 | Intraoperative |
|
|
|
| Secondary | End-Tidal CO2 Level at Time 15 | End-Tidal CO2 level recorded at 15 min during the operative procedure | Posted | Mean | Standard Deviation | Percent CO2 | Intraoperative |
|
|
|
| Secondary | End-Tidal CO2 Level at Time 30 | End-Tidal CO2 level recorded at 30 min during the operative procedure | Posted | Mean | Standard Deviation | Percent CO2 | Intraoperative |
|
|
|
| Secondary | End-Tidal CO2 Level at Time 45 | End-Tidal CO2 level recorded at 45 min during the operative procedure | Posted | Mean | Standard Deviation | Percent CO2 | Intraoperative |
|
|
|
| Secondary | End-Tidal CO2 Level at Time 60 | End-Tidal CO2 level recorded at 60 min during the operative procedure | Posted | Mean | Standard Deviation | Percent CO2 | Intraoperative |
|
|
|
| Secondary | Duration of Procedure | Time from placement of last surgical port to colpotomy (hysterectomy) or closure of last uterine defect (myomectomy) | Posted | Mean | Standard Deviation | Minutes | Intraoperative |
|
|
|
| Secondary | Number of Participants With a Hospital Stay Less Than 24 Hours | The number of participants with a hospital duration of stay less than 24 hours recorded as "yes" or "no." Data represent the number of participants with a hospital stay less than 24 hours. | Posted | Count of Participants | Participants | 2 weeks following procedure completion |
|
|
|
| Secondary | Postoperative Pain Numerical Rating Scale | Post operative pain evaluated according to a numerical rating scale from 0 (no pain) to 10 (worst pain possible) | Posted | Mean | Standard Deviation | score on a scale | Before hospital discharge |
|
|
|
| Secondary | Postoperative Pain Numerical Rating Scale | Post operative pain evaluated according to a numerical rating scale from 0 (no pain) to 10 (worst pain possible) | Posted | Mean | Standard Deviation | score on a scale | 2 weeks following procedure completion |
|
|
|
| Secondary | Number of Participants That Received Post-operative Opioid Pain Medication | The number of participants that received post-operative opioid pain medication during hospital stay recorded as "yes" or "no." Data represent the number of participants that received post-operative opioid pain medication during hospital stay. | Posted | Count of Participants | Participants | Post-operative hospitalization |
|
|
|
| Secondary | Number of Participants That Received Post-operative Non-opioid Pain Medication | The number of participants that received post-operative non-opioid pain medication during hospital stay recorded as "yes" or "no." Data represent the number of participants that received post-operative non-opioid pain medication during hospital stay. | Posted | Count of Participants | Participants | Post-operative hospitalization |
|
|
|
| Secondary | Number of Participants Reporting Opioid Pain Medication Use at Follow up | The number of participants that reported opioid pain medication use at follow up visit recorded as "yes" or "no." Data represent the number of participants that reported opioid pain medication use at follow up. | Posted | Count of Participants | Participants | 2 week follow up visit |
|
|
|
| Secondary | Number of Participants Reporting Non-opioid Pain Medication Use at Follow up | The number of participants that reported non-opioid pain medication use at follow up visit recorded as "yes" or "no." Data represent the number of participants that reported non-opioid pain medication use at follow up. | Posted | Count of Participants | Participants | 2 week follow up visit |
|
|
|
| Secondary | Adverse Events Related to Procedure | Number of subjects with adverse events determined probably related or related to procedure | Posted | Count of Participants | Participants | Intraoperative up to 2 weeks post procedure |
|
|
|
| Secondary | Adverse Events Related to Smoke Clearing Device | Number of subjects with adverse events determined probably related or related to smoke clearing device | Posted | Count of Participants | Participants | Intraoperative up to 2 week follow up visit |
|
|
|
| 0 |
| 15 |
| 0 |
| 15 |
| 5 |
| 15 |
| EG001 | ARM 2 | Laparoscopic Hysterectomy per Standard of Care/no Ultravision System Laparoscopic Hysterectomy: Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System | 0 | 15 | 0 | 15 | 9 | 15 |
| EG002 | ARM 3 | Laparoscopic myomectomy with use of the Ultravision System. Ultravision System: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation. | 0 | 5 | 0 | 5 | 0 | 5 |
|
| Thrombocytosis | Blood and lymphatic system disorders | Non-systematic Assessment | Elevated platelet count |
|
| Vaginal bleeding | Reproductive system and breast disorders | Non-systematic Assessment |
|
| Mood changes | Psychiatric disorders | Non-systematic Assessment |
|
| Bell's Palsy | Nervous system disorders | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Non-systematic Assessment |
|
| Vaginal pruritus | Reproductive system and breast disorders | Non-systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | Non-systematic Assessment |
|
| Breast Surgery | Surgical and medical procedures | Non-systematic Assessment | Concomitant planned breast surgery |
|
| Bladder Perforation | Surgical and medical procedures | Non-systematic Assessment |
|
| Ovarian mass | Reproductive system and breast disorders | Non-systematic Assessment | Intra-operative identification and removal of ovarian mass |
|
| Ovarian cyst | Reproductive system and breast disorders | Non-systematic Assessment | Intra-operative identification and removal of cyst |
|
| Endometriosis lesion | Reproductive system and breast disorders | Non-systematic Assessment | Intra-operative identification and removal of endometriosis lesion |
|
Not provided
Not provided